Skip to content

    Recently Viewed

      Listening...

      Home / Latest news / Innovation /
      Johnson & Johnson receives 8 Prix Galien USA Award nominations
      Prix Galien Award Scientists

      Johnson & Johnson receives 8 Prix Galien USA Award nominations

      The company has been recognized in all four categories for the prestigious award, including “Discovery of the Decade.”

      Share Article
      share to

      If you knew you might fail at something, would you try it anyway?

      For a life scientist, failure is an inevitable—and important—part of scientific discovery.

      With no guarantee of success, scientists persevere through trial and error until they, hopefully, have that “aha!” moment. Perhaps it’s a breakthrough treatment that gives new hope, or maybe a new innovation that has the potential to advance or maintain quality of life.

      At Johnson & Johnson, we believe that scientists and scientific excellence should be supported and celebrated.

      That’s why I was so excited when eight of our innovative teams were recognized recently by the Galien Foundation with nominations for the prestigious Prix Galien USA award, one of the highest accolades in biopharmaceutical and medical technology research. The award recognizes scientists and companies for medical innovations that have the power to change the human condition.

      In a nod to the breadth of our portfolio at Johnson & Johnson, we received nominations in all four award categories, including three for the new Discovery of the Decade category, which recognizes the most outstanding innovation from the past 10 years.

      We’ll be eagerly awaiting news of the winners tonight. In the meantime, here’s a look at our nominees:

      Discovery of the Decade

      Imbruvica® (ibrutinib), a drug to treat patients with chronic lymphocytic leukemia and other blood cancers
      Stelara® (ustekinumab), a drug for adults living with moderate to severe plaque psoriasis
      CellSearch®, a test for detecting tumor cells in cancer patients with metastatic breast, prostate or colorectal cancer

      Best Pharmaceutical Agent

      Yondelis® (trabectedin), a drug to treat patients with liposarcoma or leiomyosarcoma, which are types of soft tissue sarcomas

      Best Biotechnology Product
      Darzalex® (daratumumab), a drug for relapsed/refractory myeloma, a type of blood cancer

      Best Medical Technology

      ThermoCool SmartTouch® Catheter and The Carto SmartTouch™ Software Module* for the treatment of atrial fibrillation, an irregular heartbeat that can lead to complications
      Evarrest®, a fibrin sealant patch used by surgeons
      Attune® Knee System, designed to improve range of motion and address the unstable feeling some knee replacement patients experience during everyday activities

      Regardless of the outcome of tonight’s awards, I know we have some of the most passionate and dedicated scientific talent in the world at Johnson & Johnson. Our colleagues come to work every day excited and determined to discover and develop the next innovation that will transform the lives of people around the globe.

      I couldn’t be more proud of the world-class research our teams conduct with the goal of advancing human health and making a positive impact on society.

      For more information about each of these products, including their safety information, visit their websites.

      *In the U.S., ThermoCool® Navigation Catheters are indicated for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation, when used with Carto® Systems (excluding NaviStar® RMT ThermoCool® Catheter).

      More from Johnson & Johnson

      Health & wellness
       Intense and extreme heat wave under the sun illustrating the impact of climate change

      Building climate-resilient health clinics

      When Mother Nature strikes—think triple-digit heatwaves, wildfires, hurricanes—vulnerable populations are at risk of missing out on much-needed healthcare. For Earth Day, learn how Johnson & Johnson is helping community clinics protect patients.
      Latest news
      Q1 2024-1x1.png

      What you need to know about Johnson & Johnson’s 2024 first-quarter earnings

      Here’s an infographic breakdown of the company’s first-quarter earnings results, including key highlights from its Innovative Medicine and MedTech businesses.
      Latest news
      healthcare worker in protective medical gear

      Johnson & Johnson named to Fortune’s 2024 America’s Most Innovative Companies list

      The company’s drive to develop novel solutions for the world’s toughest healthcare challenges has earned it a spot on Fortune’s second annual list.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.